SCHEMBL6160352

SCHEMBL6160352

COc1ccccc1CNC(=O)c1c[nH]c2c(c1=O)CCCC2

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.60
HPGD P15428 7/20 0.56
ALDH1A1 P00352 7/20 0.52
KDM4E B2RXH2 2/20 0.52
RCE1 Q9Y256 1/20 0.52
HTT P42858 2/20 0.50
GAA P10253 1/20 0.50
PKM P14618 1/20 0.50
MAPK14 Q16539 1/20 0.49
NPC1 O15118 1/20 0.49
MAPT P10636 2/20 0.49
LMNA P02545 1/20 0.49
PLA2G1B P04054 1/20 0.48
ATG4B Q9Y4P1 1/20 0.48
ROCK2 O75116 1/20 0.48
ROCK1 Q13464 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KMT2A Q03164 2/20 0.47
NLRP3 Q96P20 1/20 0.47
HDAC1 Q13547 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6163396 0.98 MAPK1 (0.57) MAPK1HPGDALDH1A1KDM4ERCE1
SCHEMBL6162370 0.84 GABRP (0.46) MAPK1HPGDALDH1A1MAPK14NPC1
SCHEMBL6164599 0.81 ADORA2A (0.58) HPGDALDH1A1MAPTROCK2ROCK1
SCHEMBL6160973 0.81 GABRP (0.46) HPGDALDH1A1MAPK14NPC1MAPT
SCHEMBL6162507 0.81 ADORA2A (0.55) HPGDALDH1A1NPC1LMNASMN1; SMN2
SCHEMBL6162159 0.81 ADORA2A (0.57) HPGDALDH1A1MAPTROCK2ROCK1
SCHEMBL6162143 0.81 ADORA2A (0.57) HPGDALDH1A1MAPTROCK2ROCK1
SCHEMBL6162671 0.80 HPGD (0.55) HPGDALDH1A1NPC1LMNASMN1; SMN2
SCHEMBL6162568 0.80 LMNA (0.43) HPGDALDH1A1KDM4EHTTGAA
SCHEMBL6161545 0.79 NPC1 (0.61) HPGDALDH1A1KDM4ENPC1ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1056724-B1 SUBSTITUTED CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORP (US) 2005-05-25 EP claimed
US-6448259-B1 CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR GAMMA AMINOBUTYRIC ACID BINDING SITE, THE BENZODIAZEPINE RECEPTOR; ANXIETY, SLEEP AND SEIZURE DISORDERS SEDATIVE, ANXIOLYTIC AND ANTICONVULSANT ACTIVITY NEUROGEN CORPORATION 2002-09-10 US claimed
EP-1056724-A2 SUBSTITUTED CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2000-12-06 EP claimed
WO-1999043661-A2 SUBSTITUTED CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1999-09-02 WO claimed
EP-1056724-B1 SUBSTITUTED CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORP (US) 2005-05-25 EP disclosed
US-6448259-B1 CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR GAMMA AMINOBUTYRIC ACID BINDING SITE, THE BENZODIAZEPINE RECEPTOR; ANXIETY, SLEEP AND SEIZURE DISORDERS SEDATIVE, ANXIOLYTIC AND ANTICONVULSANT ACTIVITY NEUROGEN CORPORATION 2002-09-10 US disclosed
US-6194427-B1 BRAIN DISORDERS; PSYCHOLOGICAL DISORDERS; SLEEP DISORDERS; ANTICONVULSANTS NEUROGEN CORPORATION 2001-02-27 US disclosed